Actively Recruiting
Phase I Trial of Personalized Natural Killer Cell Therapy for Liver Cancer Hepatocellular Carcinoma
Led by Dr Cipto Mangunkusumo General Hospital · Updated on 2023-09-26
3
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating a phase I clinical trial using autologous natural killer NK cell therapy for patients with liver cancer, specifically hepatocellular carcinoma HCC classified as Child-Pugh A and Barcelona Clinic Liver Cancer BCLC stages B or C. The study aims to find the appropriate treatment dosage, monitor side effects, and determine the average progression-free survival time. Participants include liver cancer patients treated at Cipto Mangunkusumo Hospital between May and December 2022 who meet specific health criteria. The treatment involves harvesting NK cells from the patients own body and infusing them back intravenously. Dosages are personalized based on each patients condition and response. The treatment duration varies and may take several weeks to fully assess effectiveness and potential impacts. The study also uses the CliniMACS Plus device to isolate the NK cells using specialized technology. Participants will be monitored for up to six months to determine the optimal dosage and evaluate tumor shrinkage, immune responses, and blood health. Progression-free survival will be tracked for up to two years or until disease progression or death. The study includes regular assessments and lab tests to understand treatment effects and safety during this period.
CONDITIONS
Brief Title
Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma
Research Team
A
Ardhi Rahman Ahani, MD
F
Firshan Makbul, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
